Form 4: Enanta CSO Sells Shares for Tax Obligations

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, sold 2,390 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals Inc. (ENTA), reported a sale of 2,390 shares of common stock.
• The transaction occurred on December 5, 2025, at a weighted-average price of $14.23 per share, with individual sales ranging from $13.89 to $14.46.
• The shares were sold to cover withholding taxes due to the settlement of a restricted stock unit (RSU) award granted on November 23, 2022.
• This was explicitly stated as a 'sell to cover' transaction and not a discretionary sale by the reporting person.
• Following the transaction, Or Yat Sun beneficially owns 371,392 shares of Enanta Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not reflect a change in management's investment sentiment towards the company.

Positives

• The underlying restricted stock unit award, granted on November 23, 2022, represents a form of equity compensation for the Chief Scientific Officer, aligning management's interests with shareholders.

Future Outlook

NA

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

Insider transactions, particularly 'sell to cover' sales for tax purposes upon the vesting of restricted stock units, are common and routine events in publicly traded companies across all industries, including pharmaceuticals. These transactions are typically not indicative of management's sentiment regarding the company's future performance but rather a standard mechanism for managing equity compensation.

Comparison to Industry Standards

• The 'sell to cover' mechanism for satisfying tax obligations upon RSU vesting is a widely adopted practice across U.S. public companies, including peers in the biotechnology and pharmaceutical sectors. This transaction aligns with standard corporate compensation and tax management practices.

Stakeholder Impact

• Shareholders may observe a minor, non-discretionary reduction in insider holdings, which is a routine event for equity compensation vesting and typically has minimal impact on stock sentiment.

Key Dates

Recommendation

The transaction is a non-discretionary 'sell to cover' to satisfy tax obligations from a restricted stock unit award. It does not indicate a change in the reporting person's confidence in the company or provide new fundamental information to warrant a change in investment recommendation.

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Or Yat Sun, Chief Scientific Officer